Compare · ADCT vs NVS
ADCT vs NVS
Side-by-side comparison of ADC Therapeutics SA (ADCT) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADCT and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 2172.6x ADCT ($131.0M).
- Over the past year, ADCT is down 77.8% and NVS is up 24.5% - NVS leads by 102.3 points.
- ADCT has hit the wire 12 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 19 for ADCT).
- Company
- ADC Therapeutics SA
- Novartis AG
- Price
- $0.79-22.63%
- $147.10-1.32%
- Market cap
- $131.0M
- $284.62B
- 1M return
- -78.85%
- +1.06%
- 1Y return
- -77.79%
- +24.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 0
- Recent ratings
- 19
- 25
ADC Therapeutics SA
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ADCT
- ADC Therapeutics downgraded by H.C. Wainwright
- ADC Therapeutics downgraded by RBC Capital Mkts with a new price target
- Director Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax
- Director Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation
- Director Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)
- Director Monges Viviane was granted 45,000 shares and covered exercise/tax liability with 2,596 shares, increasing direct ownership by 29% to 186,447 units (SEC Form 4) to cover withholding tax
- Director Hug Peter was granted 45,000 shares and covered exercise/tax liability with 2,156 shares, increasing direct ownership by 19% to 263,344 units (SEC Form 4) to cover withholding tax
- Director Bizzari Jean-Pierre was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 139,302 units (SEC Form 4) to satisfy withholding tax
- Director Coughlin Timothy was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 81% to 72,400 units (SEC Form 4) (tax withholding)
- ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG